Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono and Pfizer to ally on lupus gene research

Merck Serono and Pfizer to ally on lupus gene research

7th April 2014

Merck Serono has announced a new lupus-focused collaboration with Pfizer and the Broad Institute in Cambridge, Massachusetts.

The alliance will centre on the genomic profiling of systemic lupus erythematosus and lupus nephritis patients, with Merck Serono and Pfizer both providing funding, while the Broad Institute will lend its extensive expertise.

Scientists from the Broad Institute will investigate clinical samples obtained from lupus patients and apply biochemical and next-generation sequencing technologies to identify biomarkers to better define target patient populations for future therapies, as well as novel treatment targets.

Merck Serono and Pfizer, as sponsoring members of the collaboration, will in return receive real-time access to all data and analysis.

Harsukh Parmar, head of the translational innovation platform for immunology and neurodegenerative diseases at Merck Serono, said: "Combined with the Broad Institute's technical knowhow, we see this collaboration aiming for a significant contribution to potential future innovative treatments of lupus and lupus nephritis."

This comes after the firm last month launched its new Oncology Partnership and Education Network, which aims to improve patient outcomes in metastatic colorectal cancer.ADNFCR-8000103-ID-801710274-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.